| pubmed-article:18076369 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18076369 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:18076369 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:18076369 | lifeskim:mentions | umls-concept:C0000936 | lld:lifeskim |
| pubmed-article:18076369 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:18076369 | lifeskim:mentions | umls-concept:C1621296 | lld:lifeskim |
| pubmed-article:18076369 | lifeskim:mentions | umls-concept:C1519814 | lld:lifeskim |
| pubmed-article:18076369 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18076369 | pubmed:dateCreated | 2007-12-13 | lld:pubmed |
| pubmed-article:18076369 | pubmed:abstractText | The sigma1 receptor is an intracellular molecule that shares no homology with any mammalian proteins. sigma1 receptors normally localize at the endoplasmic reticulum and regulate a variety of signal transductions including intracellular Ca2+ dynamics and neurotrophic factor signaling. In the brain, sigma1 receptors are known to regulate the activity of diverse ion channels via protein-protein interactions. Accumulated evidences strongly indicate that the activation/upregulation of sigma1 receptors promotes the neuronal differentiation as well as a robust antiapoptotic action. In animals, sigma1 receptor agonists exhibit an antidepressant-like action. Furthermore, the agonists enhanced neuronal survival eventhough they were administered several hours after a brain ischemia. Thus, primary clinical targets of sigma1 receptor ligands are proposed to include stroke, neurodegenerative disorders and depression. Ligands for the sigma1 receptor may constitute a new class of therapeutic drugs targeting an endoplasmic reticular protein. | lld:pubmed |
| pubmed-article:18076369 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18076369 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076369 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18076369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076369 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076369 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18076369 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18076369 | pubmed:issn | 1744-7631 | lld:pubmed |
| pubmed-article:18076369 | pubmed:author | pubmed-author:HayashiTeruoT | lld:pubmed |
| pubmed-article:18076369 | pubmed:author | pubmed-author:SuTsung-PingT... | lld:pubmed |
| pubmed-article:18076369 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18076369 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:18076369 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18076369 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18076369 | pubmed:pagination | 45-58 | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:meshHeading | pubmed-meshheading:18076369... | lld:pubmed |
| pubmed-article:18076369 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18076369 | pubmed:articleTitle | An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. | lld:pubmed |
| pubmed-article:18076369 | pubmed:affiliation | IRP, NIDA-NIH, Cellular Pathobiology Unit, Development and Plasticity Section, Cellular Neurobiology Research Branch, Room 3418, Triad building, 333 Cassell Drive, Baltimore, MD 21224, USA. thayashi@intra.nida.nih.gov | lld:pubmed |
| pubmed-article:18076369 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18076369 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:18076369 | pubmed:publicationType | Research Support, N.I.H., Intramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18076369 | lld:pubmed |
